Results for 'immune cells'

Kenji Omae, Yuki Kataoka, Yasushi Tsujimoto, Yusuke Tsutsumi, Yosuke Yamamoto, Shunichi Fukuhara, Toshi A Furukawa

Publication statuses of clinical trials supporting FDA-approved immune checkpoint inhibitors: a meta-epidemiological investigation

Anticancer drugs, Clinical trials, Drug approval, Immune checkpoint inhibitors, Publications, United states food and drug administration

  The study investigates the publication status of clinical trials for anticancer drugs approved by the FDA, focusing on immune checkpoint inhibitors (ICPis). Data from ICPis approved between 2011 and 2014 was analyzed, revealing that 58% of ICPis trials were published within two years …

Oct 24^th • 18 mins read

Alison Betts, Piet H. van der Graaf

Mechanistic Quantitative Pharmacology Strategies for the Early Clinical Development of Bispecific Antibodies in Oncology

bispecific antibodies, mechanistic quantitative, pharmacology, strategies, bsAbs, immune cells, MABEL aproach

Bi-specific antibodies (bsAbs) are crucial in cancer therapy research. BsAbs offer advantages such as enhanced efficacy and reduced systemic toxicity. Early clinical trials face challenges with dose selection and predicting effective doses. Clinical variability is influenced by factors like fun…

Jun 24^th • 18 mins read

Kirill Peskov, Ivan Azarov, Lulu Chu, Veronika Voronova, Yuri Kosinsky, Gabriel Helmlinger

Quantitative Mechanistic Modeling in Support of Pharmacological Therapeutics Development in Immuno-Oncology

immuno-oncology, mechanistic models, tumor vs. immune system, systems pharmacology, pharmacokinetics, pharmacodynamics, molecular and cellular biomarkers

There has been significant growth in the development of immuno-modulating pharmacological treatments for various cancers following the approval of the first immune checkpoint inhibitor. Challenges in immuno-oncology (IO) drug development are complex and span from the discovery phase to late-…

Apr 30^th • 12 mins read

Thomas Schmitt

Reagent Solutions to Support Outbreak Response Against Bundibugyo Virus

Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegaviral…

Sep 4^th • 0 min read

Thomas Schmitt

Reagent Solutions to Support Outbreak Response Against Bundibugyo Virus

Ebola haemorrhagic fever is a syndrome that can lead to death within a few days of the onset of symptoms. It directly affects the immune system and the vascular bed, resulting in an extremely high mortality rate. The Ebola virus (EBOV) belongs to the Filoviridae family within the order Mononegaviral…

Sep 4^th • 0 min read

David J. Segarnick, PhD, Chief Medical Officer, Educational Resource Systems and David E. Wazer, MD, FACRO, FABS, FACR, FASTRO

From Genomic Testing to Digital Biomarkers: The Expanding Role of Biomarkers in Oncology

oncology biomarkers, precision oncology, predictive biomarkers

Biomarkers have moved from the margins of oncology to the center of clinical decision-making. They now help establish diagnosis and prognosis, identify patients most likely to benefit from targeted therapy or immunotherapy, monitor response, detect molecular residual disease and emerging resistance,…

Aug 20^th • 35 mins read

Deeksha Joshi, Rubiya Khursheed, Saurabh Gupta, Diksha Wadhwa, Thakur Gurjeet Singh, Sumit Sharma, Sejal Porwal, Swati Gauniyal, Sukriti Vishwas, Sanjay Goyal, Gaurav Gupta, Rajaraman D. Eri, Kylie A. Williams, Kamal Dua, Sachin Kumar Singh

Biosimilars in Oncology: Latest Trends and Regulatory Status

oncology, biologics, biosimilars, regulatory framework, traceability

Biologic-based medicines are crucial in treating various diseases, particularly cancer, and hold a significant portion of the global pharmaceutical market. Biosimilars, which are highly similar to biologic drugs but not identical, offer potential benefits such as enhanced access and cost savings,…

Dec 5^th • 20 mins read

Alyson Haslam, PhD; Vinay Prasad, MD, MPH

Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

checkpoint inhibitor drugs, immunotherapy drugs, FDA, checkpoint, inhibitor, drugs

If FDA-approved checkpoint inhibitor drugs are universally available, we estimated that the proportion of US patients with cancer who could be eligible for such drugs is approximately 44%, while approximately 13% have a response to these drugs. These estimates, although modest, are better than estim…

May 3^rd • 10 mins read